Biotechnology, Pharmaceuticals, Vaccines, Healthcare/Life Sciences, Biopharmaceuticals, Specialized Drugs/Medications, Corporate/Industrial News, Political/General News, Respiratory Tract Diseases

Biotechnology, Pharmaceuticals

Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies Say

Pfizer-BioNTech's Covid-19 booster shot was 95.6% effective in a large study that took place while the Delta variant was prevalent, the companies say

10/21/2021 4:45:00 PM

Pfizer-BioNTech's Covid-19 booster shot was 95.6% effective in a large study that took place while the Delta variant was prevalent, the companies say

The study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.

Coronavirus Briefing and Health WeeklyGet a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.PREVIEWSUBSCRIBE“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Albert Bourla, Pfizer Chief Executive Officer.

Live updates: US announces travel restrictions over new Covid-19 variant Mariah Carey & ‘Charlie Brown Christmas’ Top Billboard’s Greatest of All Time Holiday Charts Why these students are dreading their 21st birthdays

The results were the first from a study testing whether an additional dose of a Covid-19 vaccine provides protection in people. Up until now, companies have reported a booster increased antibody levels but not tied the immune response specifically to whether that meant increased protection.

Based on the antibody data, U.S. health authorities in Septemberauthorized a third doseof the Pfizer-BioNTech vaccine for adults 65 years and older and others at high risk.The data could help the U.S. Food and Drug Administration as it weighs whether to broaden Pfizer’s booster use beyond the seniors and high-risk people permitted under current authorization. headtopics.com

The companies said they planned to submit the data to health authorities in the U.S. and other countries.The companies reported the findings in a press release and provided few medical details. The results haven’t been published in a peer-reviewed medical journal.

“Based on these findings we believe that, in addition to broad global access to vaccines for everyone, booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy,” said BioNTech CEO Ugur Sahin.In the study, the companies enrolled more than 10,000 people who were 16 years and older and had received the two-dose shot. Pfizer and BioNTech enrolled subjects in the U.S., Brazil and South Africa who had been part of the late-stage study that led to the vaccine’s original authorization. Half of the subjects got a booster dose, and the rest took a placebo.

On average, the people received a booster dose 11 months after their second dose.The protection from the vaccine was consistent across age, sex, race, ethnicity and comorbidities, the companies said, although they didn’t provide any details.About half of the subjects were between 16 and 55 years, while nearly one-quarter of the subjects were 65 years and older.

The companies had announced that a third doseagainst the original Covid-19 strain compared with the original two-dose course.As part of its application for booster authorization in September, Pfizer and BioNTech hadantibody data of the vaccine against the Delta variant in a small number of subjects. headtopics.com

Ancient case of disease spillover discovered in Neanderthal man who got sick butchering raw meat Lady Gaga’s 15 Best Ballads: From ‘Speechless’ to ‘Shallow’ High alert: World scurries to contain new COVID variant | AP News Read more: The Wall Street Journal »

Explainer: What we know so far about El Salvador's volcano-powered bitcoin bond

El Salvador plans to build the world's first 'Bitcoin City' with money from a $1 billion bitcoin-backed bond the country's President Nayib Bukele said on Saturday.

Sample size 10,000. 5,000 received placebo 5,000 booster shot. 109 in the placebo group got symptomatic Covid and 5 in the booster group got symptomatic Covid. 109/114 = 0.95614. 0.9564 x 100 = 95.6%. 109/5,000 = 2.18%. 5/5,000 = 0.1%. ~2% of placebo group had symptomatic Covid. 🙈🙉🙊 Hahah now where have I seen this before

Of course what else could Pfizer say? Large study for what duration? This whole vax thing stinks. It’s time to grant these vax full authorization so these greedy pharm companies can be hold liable soon for damages. If I had gotten 2 shots of something that was originally sold as being 95% effective at completely stopping a virus that has a 99% survival rate...then told I needed to get a 3rd shot because the first 2 weren't good enough... I'd at the very least start to believe I was lied to.

Okay and how long does it’s immunity last. 3 months? Fuck outta here OKAY OKAY I'M INFORMED 💯 Well there’s delta plus out now, time for another booster And Moderna?

Pfizer vaccine is 93% effective in preventing Covid-19 hospitalization among adolescents, CDC study findsThe Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to Covid-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children age 12 to 15 and 94% effectiveness for those age 16 to 18. A video went viral on social media in China on Thursday, showing wounded Indian soldiers captured by China in last year's Battle of the Gulwan Valley. never tell about this. AmitShah narendramodi UN ⬇️⬇️⬇️ No jab No thank you

Of course! careful roll out of VaccineBoosters is of most importance. Note that if we reached herd immunity Boosters would be unnecesary. Soon ivermictin and Hydrocloquin will be the normal treatment for Covid, big Pharma is making hay while the sun shines President Bush was in NY, attacked with his wife, they question their agents, staff today.

This sounds oddly familiar

Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant. I'm afraid, too high efficacy makes the virus turn into mutant form and danger for people who uses average or lower efficacy. Or people who don't get vaccinated It's the same 👾!

Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com No one believes this I thought the original vaccine was “95% effective against Covid 19.” Let’s stop throwing stupid numbers around, maybe then people will stop dismissing a beneficial treatment. Let them show how that is calculated. Actually quite mind blowing. Once you see it..

Pfizer booster has 95.6% efficacy against COVID, large study showsA booster shot of the Pfizer-BioNTech vaccine is 95.6% effective against the coronavirus, compared with those who only had the first two initial doses, according to a large study released Thursday.Why it matters: The study, which had more than 10,000 participants aged 16 and older, is the first controlled, randomized trial looking at boosters and their effectiveness, the companies said.Get market news worthy of your time with Axios Markets. Subscribe for free.The companies said the study was con

Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies sayA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy -- 95.6% -- against Covid-19 in a Phase 3 trial, the companies announced on Thursday. They noted that 'efficacy was consistent irrespective of age, sex, race, ethnicity or comorbid conditions.' I think we have heard the 90+% somewhere before? 🤔 How long did the efficacy last?

Pfizer Vaccine 93% Effective At Preventing Hospitalization In Kids Ages 12-18More good news about the effectiveness of Pfizer’s COVID-19 vaccine in adolescents ages 12-18 — this time, about hospitalization rates The Centers for Disease Control and Prevention just rolled out new stats pointing to Pfizer’s COVID-19 vaccine being safe and effective at preventing hospitalization in kids ages 12-18. The CDC’s latest study shows that Pfizer’s […] u are missing 84.5 million followers